



January 08, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Aditya Puri joins as Advisor to the Strides Group & Director of Stelis Biopharma”

Thanks & Regards,
For **Strides Pharma Science Limited**,

A handwritten signature in blue ink that reads 'Manjula R.'.

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

Aditya Puri joins as Advisor to the Strides Group & Director of Stelis Biopharma

Bengaluru, January 08, 2021: Strides Pharma Science Limited ('Strides') is pleased to announce that eminent corporate doyen Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma ('Stelis').

Recognized as a stalwart of the Indian banking and financial services industry, Mr. Puri was the iconic founder-Managing Director and Chief Executive Officer of HDFC Bank from its inception in 1994 until his retirement from the position in October 2020, earning the distinction of having been the longest-serving head of a private bank in India. Under his stewardship, the publicly traded bank scaled great heights to become India's largest private sector lender by assets, India's most valuable bank by market capitalization⁽¹⁾ and India's most valuable brand for the sixth consecutive year in 2019⁽²⁾. Not only was Mr. Puri's visionary leadership instrumental in HDFC Bank's outstanding growth and value creation for all stakeholders, but it also led the way for several firsts and milestones for Indian private sector banking as a whole. Prior to setting up HDFC Bank, he was Chief Executive Officer of Citibank Malaysia with nearly two decades of overall banking experience across markets with Citibank. Mr. Puri has been conferred with several prestigious awards, accolades and titles for his exceptional contribution to Indian industry, including successive appearances in Barron's world's 30 best CEOs lists, Fortune's global top 50 business persons list in 2016, the India Today Power List for 2019, and the Lifetime Achievement Award by Euromoney Awards of Excellence 2020, to name a few. Mr. Puri was inducted into the Chartered Accountants Hall of Fame by the Institute of Chartered Accountants of India (ICAI), becoming the first member of ICAI to be honored with this award⁽³⁾. A profile by the *Economist* in October 2020 describing him as the world's best banker only further underlined Mr. Puri's towering international reputation.

Mr. Puri's appointment to the Stelis Board comes at an exciting juncture for the company as it transitions from its incubation phase to a consolidation and growth phase to establish itself as a partner of choice globally with the aim of bringing world-class treatments at affordable costs to patients in both emerging and developed markets.

Commenting on the development, Aditya Puri said: *"I look forward to working with Arun and building world-class institutions to produce high-quality affordable biotherapeutics and CDMO services including those needed to combat the ongoing COVID-19 pandemic. The Group's established parentage, global success and headstart in terms of basic infrastructure, gives me the opportunity to be involved in and guide Stelis and other Group endeavors in their exciting growth story."*

Commenting on the development, Arun Kumar, Founder & Chairman of the Board of Strides,
said: *"I am delighted to welcome Aditya as our Advisor and to the Stelis Board. This a huge vote of confidence in the potential of Stelis. Aditya's illustrious legacy is well-known. Having nurtured HDFC Bank since inception, his deep experience will be extremely valuable for the Strides Group and Stelis in particular. With Stelis poised for its next leg of growth, this is the right time to expand the Board, and ensure robust guidance and governance by the best possible industry minds. I look forward to working with Aditya and leveraging his expertise to take Stelis to new heights."*

About Stelis Biopharma:

Stelis Biopharma Pvt. Ltd. (Stelis) is a vertically integrated biopharmaceutical company. Stelis offers end-to-end state-of-the-art CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. Its operations include R&D, process development, scale-up & end-to-end cGMP manufacturing capabilities from drug substance through drug product in all formats and packaging. Stelis is also developing follow-on biologic products for global markets in niche and commercially attractive disease categories. Stelis' state-of-the-art research & development facility and 200,000 sq. ft. fully integrated cGMP manufacturing facility are located in Bengaluru, India. Facilities cater to the development and cGMP manufacturing of biologics and injectables conforming to international standards.

About Strides Pharma Science Limited:

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available on the Company's website at www.strides.com.

For further information, please contact:

| | |
|--|--|
| <u>Strides</u> Badree Komandur Executive Director - Finance +91 80 6784 0747 | <u>Corporate Communication</u> Usha Iyer: +91 9987444106 Email: usha.iyer@strides.com |
| <u>Investor Relations</u> Sandeep Baid: +91 80 6784 0791 Email: Sandeep.baid@strides.com | <u>PR Consultancy</u> Veritas Reputation PR Mansi Shah: +91 98706 31556 mansi@veritasreputation.com |
| <u>Strides Pharma Science Limited</u> CIN: L24230MH1990PLC057062 | Christensen IR Diwakar Pingle: +91 98339 04971 dpingle@christensenir.com |

| | |
|--|--|
| Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703 | |
|--|--|

| | |
|--|--|
| Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560 076 | |
|--|--|

References:

- (1) https://v1.hdfcbank.com/htdocs/aboutus/News_Room/pdf/HDFC-Bank-most-valuable.pdf
- (2) HDFC Bank Limited Integrated Annual Report 2019-20, pgs 3, 12
- (3) HDFC Bank Limited Integrated Annual Report 2019-20, pg 287